OBJECTIVES To answer the question "In patients presenting with ST elevation acute myocardial infarction (STEMI) and no contraindication to thrombolysis, does the introduction of Tenecteplase reduce door to needle times?" METHODS Firstly, an observational study was performed to compare the time taken to prepare standard thrombolytic therapy with Tenecteplase. Secondly, door to needle times wer...

BACKGROUND AND PURPOSE We compared the fibrinolytic activity of tenecteplase and alteplase in patients with acute ischemic stroke, and explored the association between hypofibrinogenaemia and intracerebral hemorrhage. METHODS Venous blood samples from a subgroup of participants in the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at pretreatment,...

BACKGROUND AND PURPOSE Intravenous alteplase (rtPA) remains the only approved treatment for acute ischemic stroke, but its use remains limited. In a previous pilot dose-escalation study, intravenous tenecteplase showed promise as a potentially safer alternative. Therefore, a Phase IIB clinical trial was begun to (1) choose a best dose of tenecteplase to carry forward; and (2) to provide evidenc...

background: the aim of this study was to produce a stable cho cell line expressing tenecteplase. materials and methods: in the first step, the tenecteplase coding sequence was cloned in a pdb2 vector containing attb recognition sites for the phage φc31 integrase. then, using lipofection, the cho cells were co-transfected with constructed recombinant plasmid encoding tenecteplase and attb recogn...

OBJECTIVES This sub-study of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) trial evaluated of the impact of combination reperfusion therapy with reduced-dose tenecteplase plus eptifibatide on continuous ST-segment recovery and angiographic results. BACKGROUND Combination therapy with reduced-dose fibrinolytics and glycoprotein IIb/IIIa inhibitors for ST-segment el...

INTRODUCTION Alteplase and tenecteplase are two widely used thrombolytic agents and are both approved for the treatment of acute myocardial infarction. These two molecules have increased fibrin specificity compared with older thrombolytics but distinct pharmacokinetic properties and may differ in terms of risks and benefits. We decided to review the available evidence comparing the safety and e...

Background: Thrombolytics are recommended in high risk patients with massive pulmonary embolism (PE). However, clinical practice seems to be far different and questions related to its utility in less severely affected patients remain the subject of investigation. The objective of this observational study was to compare the efficacy and safety of tenecteplase with streptokinase and heparin. Meth...

INTRODUCTION Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase. METHODS We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute is...

tenecteplase is a variant of tissue plasminogen activator (t-pa) which has better pharmacokinetic properties and more selective thrombolytic activity. in the present study, we describe a rapid method to introduce three sets of mutation into defined positions in t-pa cdna by a site-directed mutagenesis based on a megaprimer pcr approach to produce tenecteplase coding sequence where amino acids a...